Phase II clinical trial of surgical intervention following chemotherapy for synchronous and metachronous liver metastasis from gastric cancer.(HiSCO 06)

Phase II clinical trial of surgical intervention following chemotherapy for synchronous and metachronous liver metastasis from gastric cancer.(HiSCO 06) - Phase II clinical trial of surgical intervention for liver metastasis from gastric cancer.(HiSCO 06)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024004

Enrollment

Registered

2016-09-11

Start date

2016-09-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with synchronous or metachronous liver metastasis from gastric cancer

Interventions

hepatectomy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histologically proven primary gastric adenocarcinoma. 2. Stage IV gastric cancer patients initially regarded as resectable, underwent radical operation after chemotherapy (neoadjuvant case).

Exclusion criteria

Exclusion criteria: Stage IV gastric cancer patients with peritoneal dissemination, or positive cytology para aolta LN netastasis. Patients whom doctors consider unsuitable

Design outcomes

Primary

Measure	Time frame
relapse free survival rate for 3 years	—

Secondary

Measure	Time frame
Rate of complete resction (surgical resection), and rate of curative treatment (include intervention of RFA or MCT) for hepatic lesion operative morbidigy and mortality length of postoperative hospital stay quality of life	—

Countries

Japan

Contacts

Public ContactKazuaki Tanabe

Graduate School of Biomedical and Health Sciences, Hiroshima University Department of Perioperative and Clitical Management

ktanabe2@hiroshima-u.ac.jp082-257-5222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026